A guide to selecting high-performing antibodies for STING1 (Uniprot ID: Q86WV6) for use in western blot, immunoprecipitation, and immunofluorescence
Vera Ruíz Moleón, Charles Alende, Maryam Fotouhi, Riham Ayoubi, Kathleen Southern, Carl Laflamme, Jieya Shao, Carl Laflamme, Karen Bowman
TL;DR
This paper evaluates 16 antibodies for STING1 to help researchers choose reliable ones for common lab techniques.
Contribution
The study provides a standardized evaluation of STING1 antibodies across multiple techniques to improve research reproducibility.
Findings
Sixteen commercial STING1 antibodies were tested for performance in western blot, immunoprecipitation, and immunofluorescence.
Results are shared openly to help researchers select reliable antibodies for their experiments.
The study is part of a broader initiative to improve antibody reproducibility in human protein research.
Abstract
STING1 is an immune adaptor protein which promotes innate immune defense mechanisms against pathogens. Its role in modulating inflammation links STING1 to various pathologic conditions, positioning it as a key target for therapeutic interventions aimed at regulating immune responses. To advance our understanding of STING1-associated diseases, it is essential to make high-performing antibodies readily accessible to the scientific community. This study aims to improve reliability of STING1 research as we have characterized sixteen STING1 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3| Institution | Catalog number | RRID (Cellosaurus) | Cell line | Genotype |
|---|---|---|---|---|
| Abcam | ab271147 |
| THP-1 | WT |
| Abcam | ab270493 |
| THP-1 |
|
| Company | Catalog number | Lot number | RRID (Antibody Registry) | Clonality | Clone ID | Host | Concentration (μg/μl) | Vendors recommended applications |
|---|---|---|---|---|---|---|---|---|
| Abcam | ab181125
| 1000056-10 |
| recombinant-mono | rabbit | 0.30 | Wb, IF | |
| Abcam | ab227704
| 1004954-2 |
| recombinant-mono | SP338 | rabbit | 1.50 | Wb, IF |
| Abcam | ab227705
| 1062328-1 |
| recombinant-mono | SP339 | rabbit | 0.31 | Wb |
| Abcam | ab239074
| 1001652-16 |
| recombinant-mono | EPR13130-55 | rabbit | 0.53 | Wb, IP, IF |
| ABclonal | A21051
| 6100001330 |
| recombinant-mono | rabbit | 0.29 | Wb | |
| Cell Signaling Technology | 13647
| 9 |
| recombinant-mono | D2P2F | rabbit | 0.06 | Wb, IP |
| Cell Signaling Technology | 50494
| 8 |
| recombinant-mono | D1V5L | rabbit | 0.56 | Wb, IP |
| DSHB | CPTC-STING1-1
| 4/27/23-15ug/mL |
| recombinant-mono | CPTC-STING1-1 | rabbit | 0.02 | Wb, IF |
| GeneTex | GTX134373 | 43628 |
| polyclonal | - | rabbit | 0.42 | Wb, IF |
| Novus Biologicals (Bio-Techne) | NBP2-24683 | G-4 |
| polyclonal | - | rabbit | 1.00 | Wb, IF |
| Novus Biologicals (Bio-Techne) | NBP3-18816
| COMU01 |
| recombinant-mono | 2922D | rabbit | 1.00 | Wb, IF |
| Proteintech | 19851-1-AP | 00118975 |
| polyclonal | - | rabbit | 0.70 | Wb, IP, IF |
| R&D Systems (Bio-Techne) | MAB7169
| CFWR0420041 |
| monoclonal | 723505 | mouse | 0.20 | Wb, IF |
| Thermo Fisher Scientific | 702993
| 2842286 |
| recombinant-mono | 2H1L5 | rabbit | 0.50 | Wb |
| Thermo Fisher Scientific | MA5-26030
| YJ4087701 |
| monoclonal | OTI4H1 | mouse | 1.00 | Wb, IF |
| Thermo Fisher Scientific | MA5-32768
| YJ4089249A |
| recombinant-mono | JM03-47 | rabbit | 1.00 | Wb |
| Western blot | Immunoprecipitation | Immunofluorescence |
|---|---|---|
|
|
|
|
- —Mitacs
- —Genome Quebec
- —Michael J. Fox Foundation for Parkinson’s Disease Research
- —Ontario Genomics
- —Genome Canada
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
Topicsinterferon and immune responses · Viral Infections and Vectors · Mosquito-borne diseases and control
Introduction
Stimulator of interferon genes protein (STING1) is a conserved transmembrane protein involved in innate immune response mechanisms. ^ 1 ^ ^,^ ^ 2 ^ Activated in response to bacterial cyclic dinucleotides, it initiates a cascade of signalling events inducing the production of type I interferons and inflammatory cytokines, essential molecules to activate immune response signalling. ^ 1 ^ ^,^ ^ 3 ^ ^,^ ^ 4 ^
While STING1-mediated innate immunity is involved in defending against pathogen invasion and tumor growth, aberrant expression can disrupt immune responses, ^ 5 ^ leading to autoinflammatory diseases, cancer and neurodegenerative diseases. ^ 6 ^ ^–^ ^ 8 ^ In Parkinson’s disease models, α-synuclein aggregates enhance STING1-dependent neuroinflammation and neurodegeneration. ^ 9 ^ Due to its involvement in critical immune pathways, STING1 has become a key focus for therapeutic development.
This research is part of a broader collaborative initiative in which academics, funders and commercial antibody manufacturers are working together to address antibody reproducibility issues by characterizing commercial antibodies for human proteins using standardized protocols, and openly sharing the data. ^ 10 ^ ^–^ ^ 12 ^ Here we evaluated the performance of sixteen commercial antibodies for STING1 for use in western blot, immunoprecipitation, and immunofluorescence, enabling biochemical and cellular assessment of STING1 properties and function. The platform for antibody characterization used to carry out this study was endorsed by a committee of industry academic representatives. It consists of identifying human cell lines with adequate target protein expression and the development/contribution of equivalent knockout (KO) cell lines, followed by antibody characterization procedures using most commercially available antibodies against the corresponding protein. The standardized consensus antibody characterization protocols are openly available on Protocol Exchange, a preprint server (DOI: 10.21203/rs.3.pex-2607/v1). ^ 13 ^
The authors do not engage in result analysis or offer explicit antibody recommendations. Our primary aim is to deliver top-tier data to the scientific community, grounded in Open Science principles. This empowers experts to interpret the characterization data independently, enabling them to make informed choices regarding the most suitable antibodies for their specific experimental needs. Guidelines on how to interpret antibody characterization data found in this study are featured on the YCharOS gateway. ^ 14 ^
Results and discussion
Our standard protocol involves comparing readouts from WT (wild type) and KO cells. ^ 15 ^ ^,^ ^ 16 ^ The first step was to identify a cell line(s) that expresses sufficient levels of a given protein to generate a measurable signal using antibodies. To this end, we examined the DepMap (Cancer Dependency Map Portal, RRID:SCR_017655) transcriptomics database to identify all cell lines that express the target at levels greater than 2.5 log 2 (transcripts per million “TPM” + 1), which we have found to be a suitable cut-off. ^ 10 ^ The THP-1 cell line expresses the STING1 transcript at 4.1 log 2 (TPM+1), which is above the average range of cancer cells analyzed. A STING1 KO in THP-1 was obtained from Abcam ( Table 1). THP-1 cells are small, round human leukemia monocytic cell line commonly used to study proteins involved in immune responses. Phorbol 12-myristate-13-acetate (PMA) treatment is required to differentiate THP-1 in suspension into macrophage-like adherent cells. ^ 17 ^
For western blot experiments, WT and STING1 KO protein lysates were first separated on SDS-PAGE, transferred onto nitrocellulose membranes, and then probed with sixteen STING1 antibodies in parallel ( Table 2, Figure 1).
STING1 antibody screening by western blot.Lysates from PMA-treated THP-1 WT and STING1 KO were prepared, and 40 μg of protein were processed for western blot with the indicated STING1 antibodies. The Ponceau stained transfers of each blot are presented to show equal loading of WT and KO lysates and protein transfer efficiency from polyacrylamide gels to the nitrocellulose membrane. Antibody dilutions were chosen according to the recommendations of the antibody supplier. Antibody dilution used: ab181125* at 1/1000, ab227704** at 1/200, ab227705** at 1/1000, ab239074** at 1/1000, A21051** at 1/1000, 13647** at 1/1000, 50494** at 1/1000, CPTC-STING1-1** at 1/10, GTX134373 at 1/1000, NBP2-24683 at 1/1000, NBP3-18816** at 1/1000, 19851-1-AP at 1/1000, MAB7169* at 1/1000, 702993** at 1/1000, MA5-26030* at 1/1000, MA5-32768** at 1/1000. Predicted band size: 42 kDa. *Monoclonal antibody, *Recombinant antibody.
We then assessed the capability of all sixteen antibodies to capture STING1 from THP-1 protein extracts using immunoprecipitation techniques, followed by western blot analysis. For the immunoblot step, a specific STING1 antibody identified previously (refer to Figure 1) was selected. Equal amounts of the starting material (SM) and unbound fractions (UB), as well as the whole immunoprecipitate (IP) eluates were separated by SDS-PAGE ( Figure 2).
STING1 antibody screening by immunoprecipitation.Lysates from PMA-treated THP-1 WT were prepared, and immunoprecipitation was performed using 1.0 mg of lysate and 2.0 μg of the indicated STING1 antibodies pre-coupled to Dynabeads protein A or protein G. Samples were washed and processed for western blot with the indicated STING1 antibody. For western blot, NBP3-18816* was used at 1/1000. The Ponceau stained transfers of each blot are shown. SM = 4% starting material; UB = 4% unbound fraction; IP = immunoprecipitate, HC = antibody heavy chain. *Monoclonal antibody, *Recombinant antibody.
For immunofluorescence, sixteen antibodies were screened using a mosaic strategy. First, THP-1 WT and STING1 KO cells were labelled with different fluorescent dyes in order to distinguish the two cell lines, and the STING1 antibodies were evaluated. Both WT and KO lines imaged in the same field of view to reduce staining, imaging and image analysis bias ( Figure 3). Quantification of immunofluorescence intensity in hundreds of WT and KO cells was performed for each antibody tested, and the images presented in Figure 3 are representative of this analysis. ^ 13 ^
STING1 antibody screening by immunofluorescence.PMA-treated THP-1 WT and STING1 KO cells were labelled with a green or a far-red fluorescent dye, respectively. WT and KO cells were mixed and plated to a 1:1 ratio in a 96-well plate with optically clear flat-bottom. Cells were stained with the indicated STING1 antibodies and with the corresponding Alexa-fluor 555 coupled secondary antibody including DAPI. Acquisition of the blue (nucleus-DAPI), green (identification of WT cells), red (antibody staining) and far-red (identification of KO cells) channels was performed. Representative images of the merged blue and red (grayscale) channels are shown. WT and KO cells are outlined with green and magenta dashed line, respectively. When an antibody was recommended for immunofluorescence by the supplier, we tested it at the recommended dilution. The rest of the antibodies were tested at 1 and 2 μg/ml and the final concentration was selected based on the detection range of the microscope used and a quantitative analysis not shown here. Antibody dilution used: ab181125* at 1/300, ab227704** at 1/1000, ab227705** at 1/300, ab239074** at 1/500, A21051** at 1/300, 13647** at 1/60, 50494** at 1/500, CPTC-STING1-1** at 1/20, GTX134373 at 1/1000, NBP2-24683 at 1/1000, NBP3-18816** at 1/1000, 19851-1-AP at 1/200, MAB7169* at 1/200, 702993** at 1/250, MA5-26030* at 1/1000, MA5-32768** at 1/1000. Bars = 10 μm. *Monoclonal antibody, *Recombinant antibody.
In conclusion, we have screened sixteen STING1 commercial antibodies by western blot, immunoprecipitation, and immunofluorescence by comparing the signal produced by the antibodies in human THP-1 WT and STING1 KO cells. To assist users in interpreting antibody performance, Table 3 outlines various scenarios in which antibodies may perform in all three applications. Several high-quality and renewable antibodies that successfully detect STING1 were identified in all applications. Researchers who wish to study STING1 in a different species are encouraged to select high-quality antibodies, based on the results of this study, and investigate the predicted species reactivity of the manufacturer before extending their research.
The underlying data for this study can be found on Zenodo, an open-access repository for which YCharOS has its own collection of antibody characterization reports. ^ 18 ^ ^,^ ^ 19 ^
Limitations
Inherent limitations are associated with the antibody characterization platform used in this study. Firstly, the YCharOS project focuses on renewable (recombinant and monoclonal) antibodies and does not test all commercially available STING1 antibodies. YCharOS partners provide approximately 80% of all renewable antibodies, but some top-cited polyclonal antibodies may not be available through these partners.
Secondly, the YCharOS effort employs a non-biased approach that is agnostic to the protein for which antibodies have been characterized. The aim is to provide objective data on antibody performance without preconceived notions about how antibodies should perform or the molecular weight that should be observed in western blot. As the authors are not experts in STING1, only a brief overview of the protein’s function and its relevance in disease is provided. STING1 experts are responsible for analyzing and interpreting observed banding patterns in western blots and subcellular localization in immunofluorescence.
Thirdly, YCharOS experiments are not performed in replicates primarily due to the use of multiple antibodies targeting various epitopes. Once a specific antibody is identified, it validates the protein expression of the intended target in the selected cell line, confirms the lack of protein expression in the KO cell line and supports conclusions regarding the specificity of the other antibodies. All experiments are performed using master mixes, and meticulous attention is paid to sample preparation and experimental execution. In immunofluorescence, the use of two different concentrations serves to evaluate antibody specificity and can aid in assessing assay reliability. In instances where antibodies yield no signal, a repeat experiment is conducted following titration. Additionally, our independent data is performed subsequently to the antibody manufacturers internal validation process, therefore making our characterization process a repeat.
Lastly, as comprehensive and standardized procedures are respected, any conclusions remain confined to the experimental conditions and cell line used for this study. The use of a single cell type for evaluating antibody performance poses as a limitation, as factors such as target protein abundance significantly impact results. ^ 13 ^ Additionally, the use of cancer cell lines containing gene mutations poses a potential challenge, as these mutations may be within the epitope coding sequence or other regions of the gene responsible for the intended target. Such alterations can impact the binding affinity of antibodies. This represents an inherent limitation of any approach that employs cancer cell lines.
Methods
The standardized protocols used to carry out this KO cell line-based antibody characterization platform was established and approved by a collaborative group of academics, industry researchers and antibody manufacturers. The detailed materials and step-by-step protocols used to characterize antibodies in western blot, immunoprecipitation and immunofluorescence are openly available on Protocol Exchange, a preprint server (DOI: 10.21203/rs.3.pex-2607/v1). ^ 13 ^ Brief descriptions of the experimental setup used to carry out this study can be found below.
Cell lines and antibodies used
Cell lines used and primary antibodies tested in this study are listed in Tables 1 and 2, respectively. To ensure that the cell lines and antibodies are cited properly and can be easily identified, we have included their corresponding Research Resource Identifiers, or RRID. ^ 20 ^ ^,^ ^ 21 ^ Cells were cultured in RPMI 1640 (Gibco, cat. number A1049101) containing 10% fetal bovine serum (Wisent, cat. number 080450), 0.05 mM 2-Mercaptoethanol (Gibco, cat. number 21985023, 2 mM L-glutamine (Wisent cat. number 609-065), 100 IU penicillin and 100 μg/ml streptomycin (Wisent cat. number 450201). THP-1 WT and STING1 KO cells were treated with 200 ng/ml PMA (Abcam, cat. number ab147465) for 2 days. 200 ng/ml of PMA was added to fresh medium in both day 1 and day 2. ^ 17 ^ Peroxidase-conjugated goat anti-rabbit and anti-mouse antibodies (Thermo Fisher Scientific, cat. number 65-6120 and 62-6520) and Peroxidase-conjugated Protein A (MilliporeSigma, cat. number P8651) were used in western blot and immunoprecipitation. Alexa-555-conjugated goat anti-rabbit and anti-mouse secondary antibodies (Thermo Fisher Scientific, cat. number A-21429 and A-21424) were used in immunofluorescence.
Antibody screening by western blot
PMA-treated THP-1 WT and STING1 KO cells (listed in Table 1) were collected in RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) (Thermo Fisher Scientific, cat. number 89901) supplemented with 1x protease inhibitor cocktail mix (MilliporeSigma, cat. number P8340). Lysates were sonicated briefly and incubated for 30 min on ice. Lysates were spun at ~110,000 × g for 15 min at 4°C and equal protein aliquots of the supernatants were analyzed by SDS-PAGE and western blot. BLUelf prestained protein ladder (GeneDireX, cat. number PM008-0500) was used.
Western blots were performed with precast midi 10% Bis-Tris polyacrylamide gels (Thermo Fisher Scientific, cat. number WG1201BOX) ran with MES SDS buffer (Thermo Fisher Scientific, cat. number NP000202), loaded in LDS sample buffer (Thermo Fisher Scientific, cat. number NP0008) with 1× sample reducing agent (Thermo Fisher Scientific, cat. number NP0009) and transferred on nitrocellulose membranes. Proteins on the blots were visualized with Ponceau S staining (Thermo Fisher Scientific, cat. number BP103-10) which is scanned to show together with individual western blot. Blots were blocked with 5% milk for 1 hr, and antibodies were incubated overnight at 4°C with 5% milk in TBS with 0.1% Tween 20 (TBST) (Cell Signaling Technology, cat. number 9997). Following three washes with TBST, the peroxidase conjugated secondary antibody was incubated at a dilution of ~0.2 μg/ml in TBST with 5% milk for 1 hr at room temperature followed by three washes with TBST. Membranes were incubated with Pierce ECL (Thermo Fisher Scientific, cat. number 32106) or Clarity Western ECL Substrate (Bio-Rad, cat. number 1705061) prior to detection with the iBright™ CL1500 Imaging System (Thermo Fisher Scientific, cat. number A44240).
Antibody screening by immunoprecipitation
Antibody-beads conjugates were prepared by adding 2 μg of antibody (with an exception 20 μl of antibody CPTC-STING1-1** and 20 μl of antibody 13647**) to 500 μl of Pierce IP Lysis Buffer (Thermo Fisher Scientific, cat. number 87788) in a microcentrifuge tube, together with 30μl of Dynabeads protein A- (for rabbit antibodies) or protein G- (for mouse antibodies) (Thermo Fisher Scientific, cat. number 10002D and 10004D, respectively). Tubes were rocked for ~1 hr at 4°C followed by two washes to remove unbound antibodies.
PMA-treated THP-1 WT cells were collected in Pierce IP buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol) supplemented with protease inhibitors. Lysates were rocked for 30 min at 4°C and spun at 110,000 × g for 15 min at 4°C. 0.5 ml aliquots at 2.0 mg/ml of lysate were incubated with an antibody-bead conjugate for ~1 hr at 4°C. The unbound fractions were collected, and beads were subsequently washed three times with 1.0 ml of IP lysis buffer and processed for SDS-PAGE and western blot on precast midi 10% Bis-Tris polyacrylamide gels. Protein A:HRP (MilliporeSigma, cat. number P8651) was used as a secondary detection system at a concentration of 2.0 μg/ml.
Antibody screening by immunofluorescence
PMA-treated THP-1 WT and STING1 KO cells were labelled with a green and a far-red fluorescence dye, respectively (Thermo Fisher Scientific, cat. number C2925 and C34565, respectively). The nuclei were labelled with DAPI (Thermo Fisher Scientific, cat. Number D3571) fluorescent stain. WT and KO cells were plated in a 96-well plate with optically clear flat-bottom. (Perkin Elmer, cat. number 6055300) as a mosaic and incubated for 24 hrs in a cell culture incubator, 37 ^o^C, 5% CO 2. Cells were fixed in 4% paraformaldehyde (PFA) (Beantown chemical, cat. number 140770-10 ml) in phosphate buffered saline (PBS) (Wisent, cat. number 311-010-CL) for 15 min at room temperature and then washed 3 times with PBS. Cells were permeabilized in PBS with 0.1% Triton X-100 (Thermo Fisher Scientific, cat. number BP151-500) for 10 min at room temperature and blocked with PBS with 5% BSA, 5% goat serum (Gibco, cat. number 16210-064) and 0.01% Triton X-100 for 30 min at room temperature. Cells were incubated with IF buffer (PBS, 5% BSA, 0.01% Triton X-100) containing the primary STING1 antibodies overnight at 4°C. Cells were then washed 3 × 10 min with IF buffer and incubated with corresponding Alexa Fluor 555-conjugated secondary antibodies in IF buffer at a dilution of 1.0 μg/ml for 1 hr at room temperature with DAPI. Cells were washed 3 × 10 min with IF buffer and once with PBS.
Images were acquired on an ImageXpress micro confocal high-content microscopy system (Molecular Devices), using a 20× NA 0.95 water immersion objective and scientific CMOS cameras, equipped with 395, 475, 555 and 635 nm solid state LED lights (lumencor Aura III light engine) and bandpass filters to excite DAPI, Cellmask Green, Alexa-555 and Cellmask Red, respectively. Images had pixel sizes of 0.68 × 0.68 microns, and a z-interval of 4 microns. For analysis and visualization, shading correction (shade only) was carried out for all images. Then, maximum intensity projections were generated using 3 z-slices. Segmentation was carried out separately on maximum intensity projections of Cellmask channels using CellPose 1.0, and masks were used to generate outlines and for intensity quantification. ^ 22 ^ Figures were assembled with Adobe Illustrator.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Ishikawa H Barber GN : STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674–678. 10.1038/nature 07317 18724357 PMC 2804933 · doi ↗ · pubmed ↗
- 2Ishikawa H Ma Z Barber GN : STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788–792. 10.1038/nature 08476 19776740 PMC 4664154 · doi ↗ · pubmed ↗
- 3Motwani M Pesiridis S Fitzgerald KA : DNA sensing by the c GAS-STING pathway in health and disease. Nat. Rev. Genet. 2019;20(11):657–674. 10.1038/s 41576-019-0151-1 31358977 · doi ↗ · pubmed ↗
- 4Zhang R Kang R Tang D : The STING 1 network regulates autophagy and cell death. Signal Transduct. Target. Ther. 2021;6(1):208. 10.1038/s 41392-021-00613-4 34078874 PMC 8172903 · doi ↗ · pubmed ↗
- 5Barber GN : STING: infection, inflammation and cancer. Nat. Rev. Immunol. 2015;15(12):760–770. 10.1038/nri 3921 26603901 PMC 5004891 · doi ↗ · pubmed ↗
- 6Decout A Katz JD Venkatraman S : The c GAS-STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 2021;21(9):548–569. 10.1038/s 41577-021-00524-z 33833439 PMC 8029610 · doi ↗ · pubmed ↗
- 7Zhang RX Kang R Tang DL : STING 1 in sepsis: Mechanisms, functions, and implications. Chin. J. Traumatol. 2022;25(1):1–10. 10.1016/j.cjtee.2021.07.009 34334261 PMC 8787237 · doi ↗ · pubmed ↗
- 8Glass CK Saijo K Winner B : Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918–934. 10.1016/j.cell.2010.02.016 20303880 PMC 2873093 · doi ↗ · pubmed ↗